Day: December 7, 2019

NEWPORT NEWS, Va., Dec. 07, 2019 (GLOBE NEWSWIRE) — In a ceremony celebrating the U.S. Navy’s newest nuclear-powered aircraft carrier and the American hero for whom the ship is named, Huntington Ingalls Industries’ (NYSE: HII) christened John F. Kennedy (CVN 79) today at the company’s Newport News Shipbuilding division.“We are here to celebrate America’s military might and the brawn behind it,” said Jennifer Boykin, president of Newport News Shipbuilding. “We are here to celebrate innovation, pride and perseverance that is the American way, and we are here to honor the patriot who inspired it. I speak for every Newport News shipbuilder — 25,000 strong — and the thousands of suppliers across the nation who support us when I say that we are proud to build John F. Kennedy.”Former U.S. ambassador Caroline Kennedy, the ship’s sponsor...

CAMBRIDGE, Mass., Dec. 07, 2019 (GLOBE NEWSWIRE) — Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced Phase 1 clinical updates for its Antibody-Coupled T cell Receptor (ACTR) engineered T-cell therapies, ACTR707 and ACTR087, in patients with relapsed or refractory CD20+ non-Hodgkin Lymphoma (r/r NHL) at the ASH Annual Meeting, being held December 7-10, in Orlando, FL.“The clinical data presented at this year’s ASH include updates from the ongoing Phase 1 trial of ACTR707 in combination with rituximab and the completed Phase 1 trial of ACTR087 in combination with rituximab, both conducted in patients with relapsed or refractory CD20+ NHL,” said Jessica Sachs, M.D., Chief Medical Officer of Unum. “The data with ACTR707 at this...

AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome  Data presented at 61st American Society of Hematology Annual Meeting form basis for advancement of AUTO1 into pivotal clinical trial in adult ALLInvestor call to be held December 9 at 8:30 am ET / 1:30 pm GMT to review dataLONDON, Dec. 07, 2019 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL) announced today new data highlighting progress on its next-generation programmed T cell therapies to treat patients with acute lymphoblastic leukemia (ALL) and adults with relapsed/refractory diffuse large B cell lymphoma (DLBCL).  The data were presented in oral presentations at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL.  Additional data on pediatric patients with...

CARLSBAD, Calif., Dec. 07, 2019 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today presented new data from a Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) oral solution, CV in tuberous sclerosis complex (TSC) at the American Epilepsy Society (AES) Annual Meeting. The study found that patients treated with EPIDIOLEX 25 mg/kg/day or 50 mg/kg/day experienced a significantly greater reduction in TSC-associated seizures (49% for 25 mg/kg/day and 48% for 50 mg/kg/day) compared to placebo (27%; p=0.0009 and p=0.0018, respectively).“Epilepsy is the most common neurological feature of TSC,1,2,3 a rare and severe childhood-onset disease, and as many as two-thirds...

SAN DIEGO, TORONTO and ORLANDO, Fla., Dec. 07, 2019 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a corporate event and clinical update today held at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL. The event was hosted by the Aptose management team and included Stephen B. Howell, MD, Acting Chief Medical Officer, Distinguished Professor of Medicine, Moores Cancer Center, University of California, San Diego (UCSD); with analysis by Rafael Bejar, MD, PhD, Aptose’s incoming Senior Vice President and Chief Medical Officer and currently the Director, MDS Center of Excellence, Moores Cancer Center, UCSD; and participation remotely by Brian J. Druker, MD, Chair of the Aptose Scientific Advisory Board, Professor of Medicine, Division of Hematology/Medical...

ORLANDO, Fla., Dec. 07, 2019 (GLOBE NEWSWIRE) — Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced consistent positive data from an ongoing Phase 1/2 trial of its investigational treatment, PRN1008, in 31 highly treatment-resistant and refractory patients (median of six prior therapies) with immune thrombocytopenia (ITP). The data from the trial is being presented today by David Kuter, M.D., Director of Clinical Hematology at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School, at an oral scientific session of the 61st American Society of Hematology Annual Meeting (ASH).“We are very encouraged by the data so far and pleased to see meaningful clinical responses and quick onset in this highly...

— All Oral Regimen of Once Weekly Selinexor in Combination with Daily Pomalyst® and Low Dose Dexamethasone Demonstrates 56% Overall Response Rate in Pomalyst®-Naïve and Revlimid®-Relapsed or -Refractory Myeloma with Progression-Free Survival of 12.2 Months —— Selinexor and Low Dose Dexamethasone Either Alone or in Combination with Velcade® or Kyprolis® Results in Responses in Six of Seven Patients Whose Myeloma Has Progressed Following Experimental CAR-T Therapy —NEWTON, Mass., Dec. 07, 2019 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that two presentations highlighting new and updated data relating to  XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, will be given at...

BURLINGAME, Calif., Dec. 07, 2019 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced initial results from its Phase 1/1b trial of CPI-818, the Company’s ITK-inhibitor. The early clinical data from the study demonstrated specific target engagement by CPI-818. The results were presented in a poster at the American Society of Hematology (ASH) 61st Annual Meeting 2019 in Orlando, Florida, taking place December 7-10, 2019.“We are excited to report the first clinical experience with CPI-818, our selective covalent ITK inhibitor designed to address T-cell lymphomas, a category of hematologic cancers with great need for novel therapeutic options,”...

No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing CycleNo Dose-limiting Toxicities or FT500-related SAEs Reported in First 12 Patients Treated with FT500 for Advanced Solid TumorsFavorable FT500 Phase 1 Safety, Tolerability and Immunogenicity Profile Validates Novel Multi-dose Treatment Paradigm for Off-the-shelf, iPSC-derived NK Cell ProductsSAN DIEGO, Dec. 07, 2019 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced initial clinical data for its FT516 and FT500 off-the-shelf, iPSC-derived natural killer (NK) cell product candidates.“The safety, tolerability, and immunogenicity...

Overview of Clinical Stage XEN901 and Related Patient Survey to be Presented in the “Genetic Epilepsies – Updates in the Science and Diagnosis” Exhibit in Room 318-319 on Sunday, December 8th